The Children Brain Tumor Tissue Consortium (CBTTC) is a collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors.

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML).

The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.

The goal of this study is to develop ultrasound techniques that assess blood supply to the intestines using an investigational contrast agent. Our hope is to contribute to early diagnosis and improved outcomes.

The goal of this HIE (Hypoxic Ischemic Encephalopathy) Study is to develop ultrasound techniques for detecting impaired blood supply to the brain using an investigational contrast agent.

The purpose of this study is to assess deficits in movement and coordination in children with cerebral palsy (CP) and without.

The Craniofacial Pathologies biobank is a research study collecting and storing reamining surgical specimens from the cranium and face from diagnosed patients at CHOP with a congenital craniofacial anomaly.

CTX is typically a highly progressive disease, with case reports of symptoms that first appear at any time from birth through adulthood and then worsen over time.

Cure Glomerulonephropathy Network (CureGN) is a multi-year study of 2,400 children and adults with four rare glomerular (kidney) diseases at over 50 centers in the US, Canada, and Italy.

This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism.